Research programme: kidney disorder therapeutics - Celtic Biotech IowaAlternative Names: Cardiotoxin-based therapeutics - Celtic
Latest Information Update: 09 Apr 2015
At a glance
- Originator Unknown
- Developer Celtic Biotech Iowa
- Class Cobra cardiotoxin proteins; Peptides
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Kidney disorders